2026 Interim report
Filed with HKEX · Stock code 6628 · · 77 pages · English
Summary by 6ix AI
The report indicates a significant increase in revenue, primarily driven by out-licensing and CDMO services, while also noting a decrease in research and development expenses. Additionally, the company has made notable progress in its oncology and non-oncology pipelines, including advancements in clinical trials and partnerships for drug development. The report emphasizes the company's strategic collaborations and ongoing discussions to enhance its technology platform and expand its market presence.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Transcenta Holding Limited on 6ix
Earlier from Transcenta
- Transcenta Therapeutics Presents New Data for its Novel LIV1-Targeting ADC TST013 Demonstrating Potent Anti-Tumor Activity in PDX Models of Prostate Cancer and ER Positive /HER2 Negative Breast Cancer
- Transcenta Therapeutics Appoints Dr. Christopher Hwang as Head of Global Partnerships for HiCB Platform
- Transcenta Therapeutics to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference
- Transcenta Therapeutics Announces Strategic Collaboration and Non-exclusive Licensing Agreement to Advance Integrated Continuous Biomanufacturing and Expand Global Access to Affordable Biologics
- Transcenta Therapeutics Presents Updated Efficacy Data from the Phase I/II Transtar102 Trial of Osemitamab plus Nivolumab and CAPOX in First-Line G/GEJ Cancer at ESMO Asia
Later from Transcenta
- Notification letter and reply form to registered holders
- Notification letter and request form to non-registered holders
- Cancellation and grant of award pursuant to the share incentive scheme
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement-business update on the grant of China invention patents related to osemitamab (TST001) and its companion diagnostic antibody
Follow Transcenta into a list and get an email when it puts out news.
Follow Transcenta